Applicant, as named in the Orange Book

Avyxa Holdings

Next listed expiry: Frindovyx on 1 Dec 2035. 5 products with live protection, 6 without.

Products with listed protection

Drug	Ingredient	Earliest generic entry	Basis
Frindovyx NDA 210852 · 3 strengths cyclophosphamide	cyclophosphamide	1 Dec 2035 patent	patent
Docivyx NDA 215813 · 3 strengths docetaxel	docetaxel	14 Mar 2036 patent	patent
Vykoura NDA 220406 · 3 strengths leucovorin calcium	leucovorin calcium	23 Dec 2044 patent	patent
Kyxata NDA 219921 · 2 strengths carboplatin	carboplatin	1 Apr 2045 patent	patent
Axtle NDA 210661 · 2 strengths pemetrexed dipotassium	pemetrexed dipotassium	25 Jun 2045 patent	patent

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.

Products without listed protection (6)

Drug	Ingredient	Earliest generic entry	Basis
Avgemsi NDA 219920 · 2 strengths gemcitabine hydrochloride	gemcitabine hydrochloride	open now no listed protection	no listed protection
Avopef NDA 220200 · 2 strengths etoposide	etoposide	open now no listed protection	no listed protection
Favlyxa NDA 220201 · 2 strengths fluorouracil	fluorouracil	open now no listed protection	no listed protection
Gobarden NDA 219014 bendamustine hydrochloride	bendamustine hydrochloride	open now no listed protection	no listed protection
Navitrux NDA 220436 fosaprepitant dimeglumine	fosaprepitant dimeglumine	open now no listed protection	no listed protection
Posfrea NDA 203050 palonosetron hydrochloride	palonosetron hydrochloride	open now no listed protection	no listed protection